Market Overview

UPDATE: Sterne Agee Reiterates On Intuitive Surgical Ahead Of Advisory Committee

Share:
Related ISRG
Vetr Downgrades Intuitive Surgical To 3 Stars
Lightning Round: Jim Cramer Weighs In On Juno Therapeutics, Halliburton And More
5 Companies Hit 5—-Week Highs (GuruFocus)

In a report published Wednesday, Sterne Agee analyst Gregory P. Chodaczek reiterated a Neutral rating on Intuitive Surgical (NASDAQ: ISRG), and raised the price target from $380.00 to $400.00.

In the report, Sterne Agee noted, “The FDA will convene a Medical Device Advisory Committee July 10-11 based on its previous safety advisory discouraging doctors from using power morcellators to remove fibroids. We believe this outcome will move from discouragement to an FDA requirement of a ‘boxed warning' related to the risk of cancer spread using power morcellation. Although we believe this warning will negatively affect Intuitive Surgical, we maintain our Neutral rating with a new price target of $400.00.”

Intuitive Surgical closed on Tuesday at $377.60.

Latest Ratings for ISRG

DateFirmActionFromTo
Jul 2017Morgan StanleyMaintainsOverweight
Jun 2017Cantor FitzgeraldInitiates Coverage OnNeutral
May 2017Goldman SachsInitiates Coverage OnBuy

View More Analyst Ratings for ISRG
View the Latest Analyst Ratings

Posted-In: Gregory P. Chodaczek Sterne AgeeAnalyst Color Price Target Analyst Ratings

 

Related Articles (ISRG)

View Comments and Join the Discussion!